Motion Sickness Relief Tablet
NDC 11673-354
Product Information
Motion Sickness Relief (dimenhydrinate 50 mg) is a OTC MONOGRAPH DRUG-approved product labeled by Target Corporation. Dimenhydrinate is an antihistamine used to prevent and treat nausea, vomiting and dizziness caused by motion sickness when medication cannot be given by mouth. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 11673-354 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
TCL352
Code Structure Chart
Product Details
What is NDC 11673-354?
What are the uses of this product?
What are Active Ingredients of this product?
- DIMENHYDRINATE 50 mg/1 - A drug combination that contains diphenhydramine and theophylline. It is used for treating VERTIGO, MOTION SICKNESS, and NAUSEA associated with PREGNANCY.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DIMENHYDRINATE (UNII: JB937PER5C)
- 8-CHLOROTHEOPHYLLINE (UNII: GE2UA340FM) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MINERAL OIL (UNII: T5L8T28FGP)
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 198603 - dimenhyDRINATE 50 MG Oral Tablet
- RxCUI: 198603 - dimenhydrinate 50 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.